Medpace Holdings, Inc.
NASDAQ:MEDPMedical - Diagnostics & Research
-$4.51 today
- Market cap
- $18.09B
- Beta
- 1.18
- P/E (TTM)
- 28.2
- EPS (TTM)
- $16.19
Volume 0.21M
Average 0.36M
MEDP Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Medpace Holdings, Inc.NASDAQ: MEDP
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation growth accelerates
Q3 FY2026 stock-based compensation of $7.6M rose 20.3% year over year, ahead of the -35.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 74.9% from the prior quarter. Over 3 fiscal years it compounded at +17.6% a year.
Context
- Stock-based compensation amounted to 1.4% of revenue in FY2025, up 0.2 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +20.3% holds above the trailing-twelve-month pace of -35.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 34.79M USD
- Year-over-year change
- +36.3%
- 4-year CAGR
- +24.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.79M | +36.3% |
| FY2024 | 2024-12-31 | 25.51M | +24.4% |
| FY2023 | 2023-12-31 | 20.52M | -4.2% |
| FY2022 | 2022-12-31 | 21.41M | +48.0% |
| FY2021 | 2021-12-31 | 14.47M | — |
Stock-Based Compensation vs competitors
How MEDP compares with its peers on the latest reported figures
- MEDP's LTM Sep 2026 stock-based compensation of $22.49M is the smallest of the 5 companies compared; the peer median is $121.43M.
- Its year-over-year change of -35.8% is the lowest of 5, against a peer median of +19.5%.
- Stock-based compensation amounts to 0.8% of revenue for MEDP, versus a peer median of 1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $275M | +17.5% | +8.4% | 1.6% | |
| LTM Jun 2026 | $177.43M | +291.4% | +13.1% | 2.1% | |
| LTM Jun 2026 | $65.43M | -2.0% | -1.2% | 1.6% | |
FTREFortrea Holdings Inc. | LTM Jun 2026 | $61.1M | +21.5% | +43.1% | 2.3% |
| LTM Sep 2026 | $22.49M | -35.8% | +17.6% | 0.8% | |
| Peer median (excluding MEDP) | $121.43M | +19.5% | +10.7% | 1.9% | |
Competitors are the stored peer set for MEDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 181.85M | 245.37M | 282.81M | 404.39M | 451.12M |
| Depreciation & Amortization | 21.12M | 22.34M | 26.33M | 29.25M | 28.12M |
| Deferred Income Tax | (37.11M) | (23.01M) | (25.12M) | (26.63M) | 80.77M |
| Stock-Based Compensation | 14.47M | 21.41M | 20.52M | 25.51M | 34.79M |
| Change in Working Capital | 66.71M | 106.06M | 106.49M | 157.18M | 96.28M |
| Accounts Receivables | (24.98M) | (66.92M) | (48.28M) | 2.24M | (106.22M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.87M | 6.43M | 1.05M | (2.97M) | 2.63M |
| Other Working Capital | 89.82M | 166.54M | 153.72M | 157.9M | 199.86M |
| Other Non-Cash Items | 16.3M | 15.89M | 22.35M | 19.12M | 22.14M |
| Operating Cash Flow | 263.33M | 388.05M | 433.37M | 608.82M | 713.22M |
| Capital Expenditures | (28.27M) | (36.88M) | (36.65M) | (36.55M) | (31.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (3.09M) | (1.86M) | 2.02M | 8.24M | 216K |
| Investing Cash Flow | (31.36M) | (38.74M) | (34.63M) | (28.31M) | (31.14M) |
| Debt Repayment | 0 | 50M | (50M) | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 57M |
| Common Stock Repurchased | (62.1M) | (847.85M) | (144.02M) | (169.87M) | (917.39M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 17.64M | 22.07M | 11.38M | 15.86M | 0 |
| Financing Cash Flow | (44.45M) | (775.78M) | (182.64M) | (154.01M) | (860.39M) |
| Effect of Forex Changes | (3.97M) | (6.57M) | 1.08M | (2.51M) | 5.92M |
| Net Change in Cash | 183.54M | (433.04M) | 217.18M | 423.99M | (172.39M) |
| Free Cash Flow | 235.06M | 351.17M | 396.73M | 572.27M | 681.87M |
Medpace Holdings, Inc.
NASDAQ:MEDP
Intrinsic Alpha fair value
Locked
Current Price
$646.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.